Asosiy kontentga oʻtish
AkademIndex

Xizmatlar

← Ishga qaytish

Ushbu ish iqtibos qilgan ishlar

130 ta ish

Ish: CTLA-4: a promising immunosuppressive immune checkpoint in prostate cancer therapy

  1. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

    F. Stephen Hodi, Steven O’Day, David F. McDermott +26

    MaqolaOchiq kirish201010 iqtibos
    ABI

  2. The role of regulatory T cells in the pathogenesis and treatment of prostate cancer

    Vahid Karpisheh, Seyedeh Mahboubeh Mousavi, Parinaz Naghavi Sheykholeslami +6

    Sharh maqola20218 iqtibos
    ABI

  3. The blockade of immune checkpoints in cancer immunotherapy

    Drew M. Pardoll

    Sharh maqolaOchiq kirish20127 iqtibos
    ABI

  4. Simultaneous blockade of TIGIT and HIF-1α induces synergistic anti-tumor effect and decreases the growth and development of cancer cells

    Mehrdad Fathi, Simin Bahmanpour, Asal Barshidi +12

    Maqola20216 iqtibos
    ABI

  5. Prostaglandin E2 as a potent therapeutic target for treatment of colon cancer

    Vahid Karpisheh, Afshin Nikkhoo, Mohammad Hojjat‐Farsangi +7

    Sharh maqola20196 iqtibos
    ABI

  6. EP4 receptor as a novel promising therapeutic target in colon cancer

    Vahid Karpisheh, Navneet Joshi, Angelina Olegovna Zekiy +5

    Sharh maqola20206 iqtibos
    ABI

  7. Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment

    Douglas Hanahan, Lisa M. Coussens

    Sharh maqolaOchiq kirish20125 iqtibos
    ABI

  8. The role of Th17 cells in the pathogenesis and treatment of breast cancer

    Vahid Karpisheh, Majid Ahmadi, Kazem Abbaszadeh‐Goudarzi +5

    Sharh maqola20225 iqtibos
    ABI

  9. The molecular biology and therapeutic potential of Nrf2 in leukemia

    Atefeh Khodakarami, Sara Adibfar, Vahid Karpisheh +6

    Sharh maqola20225 iqtibos
    ABI

  10. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

    Dung T. Le, Jennifer N. Uram, Hao Wang +32

    Maqola20155 iqtibos
    ABI

  11. Increased susceptibility to doxorubicin-induced cell death in acute lymphocytic leukemia cells by inhibiting serine/threonine WEE1 kinase expression using the chitosan-carboxymethyl dextran-polyethylene glycol-TAT nanoparticles

    Abbas Ali Hosseinpour Feizi, Sajjad Vakili‐Samiani, Vahid Karpisheh +11

    MaqolaOchiq kirish20224 iqtibos
    ABI

  12. The tumor microenvironment

    Nicole Anderson, M. Celeste Simon

    Maqola20204 iqtibos
    ABI

  13. RETRACTED: Silencing STAT3 enhances sensitivity of cancer cells to doxorubicin and inhibits tumor progression

    Navneet Joshi, Farnaz Hajizadeh, Ehsan Ansari Dezfouli +11

    Maqola20214 iqtibos
    ABI

  14. Advancing the therapeutic effectiveness of paclitaxel in chronic lymphocytic leukemia through the simultaneous inhibition of NOTCH1 and SF3B1

    Shiva Abolhasani, Armin Mahmoud Salehi Khesht, Atefeh Khodakarami +13

    Maqola20254 iqtibos
    ABI

  15. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

    Philip W. Kantoff, Celestia S. Higano, Neal D. Shore +10

    MaqolaOchiq kirish20103 iqtibos
    ABI

  16. Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches

    Mamello Sekhoacha, Keamogetswe Riet, Paballo Motloung +3

    Sharh maqolaOchiq kirish20223 iqtibos
    ABI

  17. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

    Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer +27

    MaqolaOchiq kirish20123 iqtibos
    ABI

  18. Innate immune cells in the tumor microenvironment

    Ming O. Li, Natalie K. Wolf, David H. Raulet +8

    Maqola20213 iqtibos
    ABI

  19. Enhancement of Antitumor Immunity by CTLA-4 Blockade

    Dana R. Leach, Matthew F. Krummel, James P. Allison

    Maqola19963 iqtibos
    ABI

  20. T‐cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer

    Mehrdad Fathi, Inna Pustokhina, Sergey V. Kuznetsov +5

    Sharh maqola20213 iqtibos
    ABI

  21. Pan Cyclin-Dependent Kinase Inhibitors for the Treatment of Breast Cancer

    Sepideh Izadi, Mohammad Hojjat Farsang, Vahid Karpisheh +1

    Maqola20233 iqtibos
    ABI

  22. Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment

    Lucia Lisi, Pedro Miguel Lacal, Maria Martire +2

    Sharh maqola20212 iqtibos
    ABI

  23. Phase I Trial of Anti‐PSMA Designer CAR‐T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2‐T Cell Pharmacodynamics as a Determinant of Clinical Response

    Richard P. Junghans, Qiangzhong Ma, Ritesh Rathore +8

    Maqola20162 iqtibos
    ABI

  24. 2022 Update on Prostate Cancer Epidemiology and Risk Factors—A Systematic Review

    Oskar Bergengren, Kelly R. Pekala, Konstantina Matsoukas +9

    Sharh maqolaOchiq kirish20232 iqtibos
    ABI

  25. miR-221-3p Regulates VEGFR2 Expression in High-Risk Prostate Cancer and Represents an Escape Mechanism from Sunitinib In Vitro

    Markus Krebs, Antonio Giovanni Solimando, Charis Kalogirou +10

    MaqolaOchiq kirish20202 iqtibos
    ABI